• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-Term Outcome After Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Ischemic Events.
CONCLUSION: In this long-term follow-up after PFO closure, the rate of recurrent stroke was low. There were no significant differences in event rates between different occluder devices, the existence of an atrial septal aneurysm, or grade of preprocedural shunt at baseline. Patients <45 years old had lower rates of recurrent ischemic stroke. PMID: 31368895 [PubMed - in process]
Source: The Journal of Invasive Cardiology - August 3, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

The IrisFIT Patent Foramen Ovale Closure Device in Patients With History of Cryptogenic Embolization.
CONCLUSION: The IrisFIT PFO Closure System can be used safely and with high technical success for secondary prevention of cryptogenic stroke or peripheral embolization. PMID: 31522140 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - September 16, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Percutaneous Closure of Intracardiac Defects in Adults: State of the Art.
Authors: Pineda AM, Mihos CG, Singla S, Santana O, Rhodes J, Sommer RJ, Rihal CS, Beohar N Abstract The number of adults with congenital heart disease is expected to increase over the next decade. Although acquired defects are being increasingly recognized in adults, congenital heart disease remains the most common etiology. With advances in cardiac imaging, device technology, and transcatheter techniques, percutaneous closure is now feasible and safe for most intracardiac defects. Device closure is considered the first-line therapy for a variety of congenital intracardiac defects, including ostium secundum atrial ...
Source: The Journal of Invasive Cardiology - March 11, 2016 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Propensity-Score Matched Comparison of the Cera PFO Occluder With the Amplatzer PFO Occluder for Percutaneous Closure of Patent Foramen Ovale Without Echocardiographic Guidance.
CONCLUSIONS: With regard to procedural safety and closure rate at 6 months, the performance of the CPO is comparable with the APO in this small patient cohort. PMID: 28570259 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - June 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Pages: 1  2